Table 1 Baseline characteristics of study subjects
Characteristics | Â | n(%) |
|---|---|---|
Gender (n(%)) | Male | 439(34.19) |
| Â | Female | 845(68.81) |
WHO Stage(n(%)) | SI | 372(28.97) |
| Â | SII | 398(30.99) |
| Â | SIII | 419(32.63) |
| Â | SIV | 95(7.41) |
Treatment at start(n(%)) | 1 | 526(40.96) |
| Â | 2 | 67(5.22) |
| Â | 3 | 185(14.41) |
| Â | 4 | 82 (6.39) |
| Â | 5 | 401(31.23) |
| Â | 6 | 23(1.79) |
Age (Median (IQR)) | Â | 30 (26-35) |
Baseline CD4 (Median (IQR)) | Â | 137(78-201) |
Status at the end(n(%)) | Dead | 52(4.05) |
| Â | Drop | 197(15.34) |
| Â | Transfer | 127(9.89) |
| Â | Under follow up | 908(70.72) |